Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03463275 for Cognitive Impairment in Schizophrenia
NCT01911676Phase 2Completed
- Sponsor
- Yale University
- Start
- Aug 2013
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PF-03463275 in schizophrenia, schizoaffective disorder, sponsored by Yale University. Started Aug 2013; status: completed.
02
Drugs
PF-03463275
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT01911676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01911676.